Treatment of duodenal ulcer.
Although gastric acidity is essential for the development of DU, the pathogenesis is more complex and includes an imbalance in the "defending" forces, mainly in mucous secretion, prostaglandin and bicarbonate synthesis and cell turnover. The new drugs available for inhibition of acid secretion, ulcer isolation and cytoprotection make it possible to attack the problem from different sites. The decision of which drug to choose should take into account side effects, drug interactions, cost and recurrence.
D000863:Antacids / Q000627:therapeutic use; D001729:Bismuth / Q000627:therapeutic use; D002229:Carbenoxolone / Q000627:therapeutic use; D002927:Cimetidine / Q000627:therapeutic use; D004381:Duodenal Ulcer / Q000188:drug therapy* / Q000209:etiology; D005753:Gastric Mucosa / Q000502:physiology; D006635:Histamine H2 Antagonists / Q000627:therapeutic use; D006801:Humans; D010890:Pirenzepine / Q000627:therapeutic use; D011453:Prostaglandins / Q000502:physiology; D011899:Ranitidine / Q000627:therapeutic use
D000863:Antacids; D006635:Histamine H2 Antagonists; D011453:Prostaglandins; D010890:Pirenzepine; D002927:Cimetidine; D011899:Ranitidine; D002229:Carbenoxolone; D001729:Bismuth